AQR Capital Management
KALV

AQR Capital Management’s KalVista Pharmaceuticals KALV Stock Holding History

AQR Capital Management’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$756K Buy
37,572
+12,906
+52% +$208K ﹤0.01% 2912
2025
Q4 		$398K Sell
24,666
-19,940
-45% -$264K ﹤0.01% 3033
2025
Q3 		$543K Sell
44,606
-2,807
-6% -$38.8K ﹤0.01% 2777
2025
Q2 		$536K Sell
47,413
-8,562
-15% -$105K ﹤0.01% 2583
2025
Q1 		$646K Buy
+55,975
New +$571K ﹤0.01% 2278
2024
Q4 		– Sell
-12,354
Closed -$143K – 2906
2024
Q3 		$143K Buy
+12,354
New +$155K ﹤0.01% 2619
2024
Q2 		– Sell
-10,538
Closed -$125K – 2639
2024
Q1 		$125K Buy
+10,538
New +$140K ﹤0.01% 2316
2023
Q2 		– Sell
-21,848
Closed -$172K – 2235
2023
Q1 		$172K Sell
21,848
-72,436
-77% -$541K ﹤0.01% 2075
2022
Q4 		$637K Buy
+94,284
New +$505K ﹤0.01% 1724

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AQR Capital Management's KALV Position: Q1 2026 in Review

AQR Capital Management increased its KalVista Pharmaceuticals (KALV) stake by 52% in Q1 2026, buying an estimated $208K and bringing the position to 37,572 shares worth $756K. The position accounts for ﹤0.01% of the portfolio, ranked #2912.

AQR Capital Management first reported a position in KALV in Q4 2022 and has held it in 9 quarters since. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • AQR Capital Management held 37,572 shares of KalVista Pharmaceuticals worth $756K as of Q1 2026.
  • AQR Capital Management bought 12,906 KalVista Pharmaceuticals shares in Q1 2026, an estimated $208K.
  • KalVista Pharmaceuticals made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #2912 holding.
  • AQR Capital Management first reported a position in KalVista Pharmaceuticals in Q4 2022 and has held it in 9 quarters since.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.